Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY25 results · Apr–Jun 2024
Gland Pharma reported revenue from operations of ₹1,401.71 crore (up 16.0% from Q1 FY24) and net profit of ₹143.76 crore (down 25.9% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,401.71 | 1,208.69 | +16.0% | 1,537.45 | −8.8% |
| Other income | 51.43 | 37.54 | +37.0% | 42.15 | +22.0% |
| Total income | 1,453.14 | 1,246.23 | +16.6% | 1,579.60 | −8.0% |
| Profit before tax | 218.25 | 261.27 | −16.5% | 298.23 | −26.8% |
| Net profit for the period | 143.76 | 194.10 | −25.9% | 192.42 | −25.3% |
| EPS, basic (₹) | 8.73 | 11.79 | −26.0% | 11.68 | −25.3% |
| Net margin (%) | 10.3 | 16.1 | 12.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,012.02 | 884.07 | +14.5% | 1,174.83 | −13.9% |
| Other income | 48.49 | 35.21 | +37.7% | 46.95 | +3.3% |
| Total income | 1,060.51 | 919.28 | +15.4% | 1,221.79 | −13.2% |
| Profit before tax | 300.31 | 253.99 | +18.2% | 432.69 | −30.6% |
| Net profit for the period | 222.92 | 187.58 | +18.8% | 321.41 | −30.6% |
| EPS, basic (₹) | 13.53 | 11.39 | +18.8% | 19.51 | −30.7% |
| Net margin (%) | 22.0 | 21.2 | 27.4 |
Consolidated
- Filed with BSE
- 07 Aug 2024, 12:14 IST
- Board meeting
- 06 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2024, 12:14 IST
- Board meeting
- 06 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE